News | August 05, 2008

Isovue Visipaque Show No Difference in Rate of CIN

August 4, 2008 - There is no statistically significant difference between iopamidol-370 (Isovue-370) and iodixanol-320 (Visipaque-320) in the rate of contrast-induced nephropathy (CIN) in high-risk patients undergoing CT, according to findings from the PREDICT study.

The results of the Patients with REnal impairment and DIabetes undergoing Computed Tomography (PREDICT) study were just published in the American Journal of Roentgenology (Am J Roentgenol. 2008;191: 151-157). The PREDICT trial is the largest, prospective, randomized, double-blind comparison of the iso-osmolar iodixanol-320 with the low-osmolar iopamidol-370 in high-risk patients undergoing computed tomography (CT).

The purpose of this multicenter, double-blind, randomized study was to prospectively compare the incidence of CIN following administration of the nonionic monomer iopamidol-370 (Isovue -370, Bracco Diagnostics, 796 mOsm/kg) or the nonionic dimer iodixanol-320 (Visipaque 320, General Electric Healthcare, 290 mOsm/kg) in 248 patients with moderate-to-severe chronic kidney disease and diabetes mellitus. CIN was defined as increases in serum creatinine equal or above 25 percent from baseline levels, detected at 48-72 hours following administration of the two contrast media.

�The PREDICT study shows that there is no statistically significant difference in the rate of CIN between the iso-osmolar iodixanol and the low-osmolar iopamidol in patients with significant renal impairment and diabetes, i.e., in those patients that are considered at high-risk for an acute and clinically important decline in renal function following the administration of intravascular contrast media. The PREDICT study reinforces the results of earlier published studies, the IMPACT Study and the CARE Study, that also failed to find a difference between iodixanol and iopamidol when administered to at-risk patients� said Matthew J. Kuhn, MD, Chief, Division of Neuroradiology, Clinical Professor, Department of Radiology, Neurology, and Neurosurgery Southern Illinois University School of Medicine, the lead investigator and expert in CIN.

�During the last five years there has been a great deal of discussion about CIN and the safety profile of various contrast media. It has been our goal to support research which could provide valid and reliable clinical evidence to the healthcare community on this very serious topic. PREDICT1 is the third head-to-head clinical trial comparing iopamidol and iodixanol which demonstrated no statistically significant differences between the two agents in at-risk patients. The first trial, IMPACT2, compared the agents following their intravenous injection in 153 patients with chronic kidney disease undergoing CT and the second trial, CARE3, the largest study, compared these agents following their intra-arterial injection in 414 high-risk patients who were undergoing cardiac angiography or percutaneous coronary intervention. Bracco Diagnostics Inc. is committed to investing in clinical research to advance the field of medical imaging�, stated Alberto Spinazzi, MD, Sr. VP, Group Medical and Regulatory Affairs at Bracco Diagnostics Inc.

For a copy of the study: http://www.bracco.com/usa/en-US/Imaging/XRay/Isovue/

For more information: www.bracco.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init